Functional Imaging of Cerebral Blood Flow and Glucose Metabolism in Parkinson’s Disease and Huntington’s Disease

[1]  Y. Mizuno,et al.  Gene therapy for Parkinson's disease. , 2013, Journal of neural transmission. Supplementum.

[2]  David Eidelberg,et al.  Imaging markers of mild cognitive impairment: Multivariate analysis of CBF SPECT , 2007, Neurobiology of Aging.

[3]  Koen Van Laere,et al.  Quantification of Parkinson’s disease-related network expression with ECD SPECT , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[4]  David Eidelberg,et al.  Subthalamic Glutamic Acid Decarboxylase Gene Therapy: Changes in Motor Function and Cortical Metabolism , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[5]  V. Dhawan,et al.  Abnormal Metabolic Network Activity in Parkinson'S Disease: Test—Retest Reproducibility , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[6]  David Eidelberg,et al.  Metabolic brain networks associated with cognitive function in Parkinson's disease , 2007, NeuroImage.

[7]  V. Dhawan,et al.  Association between reduced striatal D2 receptor binding and the estimated time to onset in presymptomatic Huntington's disease: A longitudinal RAC/PET study over 4 years , 2006, NeuroImage.

[8]  David Eidelberg,et al.  Functional imaging of sequence learning in Parkinson's disease , 2006, Journal of the Neurological Sciences.

[9]  V. Dhawan,et al.  Network modulation in the treatment of Parkinson's disease. , 2006, Brain : a journal of neurology.

[10]  Anna Barnes,et al.  Network modulation by the subthalamic nucleus in the treatment of Parkinson's disease , 2006, NeuroImage.

[11]  Jean-Claude Baron,et al.  Decomposition of metabolic brain clusters in the frontal variant of frontotemporal dementia , 2006, NeuroImage.

[12]  Karl Herholz,et al.  18FDG PET in Vascular Dementia: Differentiation from Alzheimer's Disease Using Voxel-Based Multivariate Analysis , 2006, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[13]  James Ralph Moeller,et al.  Highly automated computer-aided diagnosis of neurological disorders using functional brain imaging , 2006, SPIE Medical Imaging.

[14]  R. P. Maguire,et al.  Corticostriatal covariance patterns of 6–[18F]fluoro–L–dopa and [18F]fluorodeoxyglucose PET in Parkinson's disease , 2006, Journal of Neurology.

[15]  Andrea Ciarmiello,et al.  Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  Jane S. Paulsen,et al.  Preclinical Huntington's disease: Compensatory brain responses during learning , 2006, Annals of neurology.

[17]  J. Pruim,et al.  Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington disease , 2005, Neurology.

[18]  B. D. de Jong,et al.  Direct comparison between regional cerebral metabolism in progressive supranuclear palsy and Parkinson's disease , 2005, Movement disorders : official journal of the Movement Disorder Society.

[19]  V. Sossi,et al.  Positron emission tomography after fetal transplantation in Huntington's disease , 2005, Annals of neurology.

[20]  Anna Barnes,et al.  FDG PET in the differential diagnosis of parkinsonian disorders , 2005, NeuroImage.

[21]  Francesca Cicchetti,et al.  Cerebral PET imaging and histological evidence of transglutaminase inhibitor cystamine induced neuroprotection in transgenic R6/2 mouse model of Huntington's disease , 2005, Journal of the Neurological Sciences.

[22]  David Eidelberg,et al.  The metabolic pathology of dopa‐responsive dystonia , 2005, Annals of neurology.

[23]  J. Stein,et al.  Effect of GPi DBS on functional imaging of the brain in dystonia , 2005, Journal of Clinical Neuroscience.

[24]  D. Perani,et al.  MCI conversion to dementia and the APOE genotype , 2004, Neurology.

[25]  Yaakov Stern,et al.  Covariance PET patterns in early Alzheimer's disease and subjects with cognitive impairment but no dementia: utility in group discrimination and correlations with functional performance , 2004, NeuroImage.

[26]  M. Vidailhet,et al.  Globus pallidus internus stimulation in primary generalized dystonia: a H215O PET study. , 2004, Brain : a journal of neurology.

[27]  A. Strafella,et al.  Bilateral globus pallidus stimulation for Huntington's disease , 2004, Annals of neurology.

[28]  J. Baron,et al.  'In the course of time': a PET study of the cerebral substrates of autobiographical amnesia in Alzheimer's disease. , 2004, Brain : a journal of neurology.

[29]  Jean-Claude Baron,et al.  Executive processes in Parkinson's disease: FDG‐PET and network analysis , 2004, Human brain mapping.

[30]  V. Dhawan,et al.  Regional metabolism in primary torsion dystonia , 2004, Neurology.

[31]  Jane S. Paulsen,et al.  A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length , 2004, Clinical genetics.

[32]  V. Sturm,et al.  Subthalamic Nucleus Stimulation Restores Glucose Metabolism in Associative and Limbic Cortices and in Cerebellum: Evidence from a FDG-PET Study in Advanced Parkinson's Disease , 2004, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[33]  John A Detre,et al.  Precision of the CASL‐perfusion MRI technique for the measurement of cerebral blood flow in whole brain and vascular territories , 2003, Journal of magnetic resonance imaging : JMRI.

[34]  Anna Barnes,et al.  Evolving metabolic changes during the first postoperative year after subthalamotomy. , 2003, Journal of neurosurgery.

[35]  Ulrike Schroeder,et al.  Subthalamic nucleus stimulation affects a frontotemporal network: A PET study , 2003, Annals of neurology.

[36]  Y. Iris Chen,et al.  Mapping of brain function after MPTP-induced neurotoxicity in a primate Parkinson's disease model , 2003, NeuroImage.

[37]  Guinevere F. Eden,et al.  Multivariate analysis of neuronal interactions in the generalized partial least squares framework: simulations and empirical studies , 2003, NeuroImage.

[38]  S. Hersch.  Huntington's disease: prospects for neuroprotective therapy 10 years after the discovery of the causative genetic mutation , 2003, Current opinion in neurology.

[39]  M. Ghilardi,et al.  Impaired sequence learning in carriers of the DYT1 dystonia mutation , 2003, Annals of neurology.

[40]  Nicola Pavese,et al.  Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. , 2003, Brain : a journal of neurology.

[41]  J. Baron,et al.  Efficient principal component analysis for multivariate 3D voxel‐based mapping of brain functional imaging data sets as applied to FDG‐PET and normal aging , 2003, Human brain mapping.

[42]  D. Eidelberg,et al.  Primary dystonia: Is abnormal functional brain architecture linked to genotype? , 2002, Annals of neurology.

[43]  Angelo Antonini,et al.  Tc‐99m ethylene cysteinate dimer SPECT in the differential diagnosis of parkinsonism , 2002, Movement disorders : official journal of the Movement Disorder Society.

[44]  Timothy J Carroll,et al.  Absolute Quantification of Cerebral Blood Flow with Magnetic Resonance, Reproducibility of the Method, and Comparison with H215O Positron Emission Tomography , 2002, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[45]  C D Good,et al.  The distribution of structural neuropathology in pre-clinical Huntington's disease. , 2002, Brain : a journal of neurology.

[46]  Frieke M. A. Box,et al.  Reproducibility of total cerebral blood flow measurements using phase contrast magnetic resonance imaging , 2002, Journal of magnetic resonance imaging : JMRI.

[47]  Alberto Pupi,et al.  Changes in regional cerebral blood flow caused by deep-brain stimulation of the subthalamic nucleus in Parkinson's disease. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[48]  David Eidelberg,et al.  Relationships among the metabolic patterns that correlate with mnemonic, visuospatial, and mood symptoms in Parkinson's disease. , 2002, The American journal of psychiatry.

[49]  Narter Ari,et al.  Test‐retest reproducibility of quantitative CBF measurements using FAIR perfusion MRI and acetazolamide challenge , 2002, Magnetic resonance in medicine.

[50]  V. Dhawan,et al.  Metabolic correlates of levodopa response in Parkinson’s disease , 2001, Neurology.

[51]  D. Eidelberg,et al.  Metabolic network abnormalities in early Huntington's disease: an [(18)F]FDG PET study. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[52]  J R Moeller,et al.  Metabolic changes following subthalamotomy for advanced Parkinson's disease , 2001, Annals of neurology.

[53]  N Makris,et al.  Striatal volume loss in HD as measured by MRI and the influence of CAG repeat , 2001, Neurology.

[54]  J R Moeller,et al.  Networks mediating the clinical effects of pallidal brain stimulation for Parkinson's disease: a PET study of resting-state glucose metabolism. , 2001, Brain : a journal of neurology.

[55]  Simon R. Cherry,et al.  Deficits in Striatal Dopamine D2 Receptors and Energy Metabolism Detected by in Vivo MicroPET Imaging in a Rat Model of Huntington's Disease , 2000, Experimental Neurology.

[56]  G. Pearlson,et al.  Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease , 2000, Movement disorders : official journal of the Movement Disorder Society.

[57]  R N Gunn,et al.  Huntington's disease progression. PET and clinical observations. , 1999, Brain : a journal of neurology.

[58]  B Conrad,et al.  A positron emission tomographic study of subthalamic nucleus stimulation in Parkinson disease: enhanced movement-related activity of motor-association cortex and decreased motor cortex resting activity. , 1999, Archives of neurology.

[59]  V. Dhawan,et al.  Reproducibility of regional metabolic covariance patterns: comparison of four populations. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[60]  S. Yamaguchi,et al.  Medication-induced hallucination and cerebral blood flow in Parkinson’s disease , 1999, Journal of Neurology.

[61]  V. Dhawan,et al.  Differential diagnosis of parkinsonism with [18F]fluorodeoxyglucose and PET , 1998, Movement disorders : official journal of the Movement Disorder Society.

[62]  D. Eidelberg,et al.  [11C]Raclopride‐PET studies of the Huntington's disease rate of progression: Relevance of the trinucleotide repeat length , 1998, Annals of neurology.

[63]  L. Bäckman,et al.  Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes. , 1997, Brain : a journal of neurology.

[64]  Karl J. Friston,et al.  Characterizing the Response of PET and fMRI Data Using Multivariate Linear Models , 1997, NeuroImage.

[65]  J R Moeller,et al.  Metabolic correlates of pallidal neuronal activity in Parkinson's disease. , 1997, Brain : a journal of neurology.

[66]  Masayuki Sasaki,et al.  Glucose metabolism in the cortical and subcortical brain structures in multiple system atrophy and Parkinson's disease: a positron emission tomographic study , 1996, Journal of the Neurological Sciences.

[67]  P Boesiger,et al.  Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. , 1996, Brain : a journal of neurology.

[68]  Karl J. Friston,et al.  Detecting Activations in PET and fMRI: Levels of Inference and Power , 1996, NeuroImage.

[69]  D. Brooks,et al.  Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease , 1996, Annals of neurology.

[70]  T. Ishikawa,et al.  Assessment of disease severity in parkinsonism with fluorine-18-fluorodeoxyglucose and PET. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[71]  T. Ishikawa,et al.  The Metabolic Topography of Parkinsonism , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[72]  J C Mazziotta,et al.  Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington's disease. , 1992, Archives of neurology.

[73]  D. Riche,et al.  A Primate Model of Huntington'S Disease: Functional Neural Transplantation and Ct-Guided Stereotactic Procedures , 1992, Cell transplantation.

[74]  W. Martin,et al.  Cortical glucose metabolism in Huntington's disease , 1992, Neurology.

[75]  M Otsuka,et al.  Striatal blood flow, glucose metabolism and 18F-dopa uptake: difference in Parkinson's disease and atypical parkinsonism. , 1991, Journal of neurology, neurosurgery, and psychiatry.

[76]  H. Herzog,et al.  Cortical and subcortical glucose consumption measured by PET in patients with Huntington's disease. , 1990, Brain : a journal of neurology.

[77]  R. Hichwa,et al.  Positron emission tomographic scan investigations of Huntington's disease: Cerebral metabolic correlates of cognitive function , 1988, Annals of neurology.

[78]  R. Hichwa,et al.  PET scan investigations of Huntington's disease: Cerebral metabolic correlates of neurological features and functional decline , 1986, Annals of neurology.

[79]  M. Hayden,et al.  Positron emission tomography in the early diagnosis of Huntington's disease , 1986, Neurology.

[80]  David Eidelberg,et al.  Neuroimaging and therapeutics in movement disorders , 2005 .

[81]  Patricia A. Broderick,et al.  Bioimaging in Neurodegeneration , 2005 .

[82]  V. Dhawan,et al.  Positron Emission Tomography and Embryonic Dopamine Cell Transplantation in Parkinson’s Disease , 2005 .

[83]  Vincent Frouin,et al.  Striatal neural grafting improves cortical metabolism in Huntington's disease patients. , 2004, Brain : a journal of neurology.

[84]  N. Volkow,et al.  Transplant of cultured neuron-like differentiated chromaffin cells in a Parkinson's disease patient. A preliminary report. , 1999, Archives of medical research.

[85]  J. M. Ollinger,et al.  Positron Emission Tomography , 2018, Handbook of Small Animal Imaging.

[86]  Evidence of cortical metabolic dysfunction in early Huntington's disease by single-photon-emission computed tomography , 1996 .

[87]  G. Alexander,et al.  Application of the scaled subprofile model to functional imaging in neuropsychiatric disorders: A principal component approach to modeling brain function in disease , 1994 .

[88]  P. Fox,et al.  Computational approaches to network analysis in functional brain imaging , 1994 .

[89]  H. Herzog,et al.  Comparison of somatosensory evoked potentials with striatal glucose consumption measured by positron emission tomography in the early diagnosis of huntington's disease , 1993, Movement disorders : official journal of the Movement Disorder Society.